Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Reporting

v3.25.1
Segment Reporting
12 Months Ended
Dec. 31, 2024
Segment Reporting  
Segment Reporting

10.Segment Reporting

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance. The Company has one reportable segment: life science. The life science segment consists of the development of clinical and preclinical product candidates. The Company’s chief operating decision maker (“CODM”) is the chief executive officer.

The accounting policies of the life science segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the life science segment based on net income (loss), which is reported on the income statement as consolidated net income (loss). The measure of segment assets is reported on the balance sheet as total consolidated assets.

To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval.

As such, the CODM uses cash forecast models in deciding how to invest into the life science segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net income (loss) is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management’s compensation, along with cash forecast models.

The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024, and 2023:

Years Ended December 31, 

2024

    

2023

Operating Expenses:

PMN310 development program costs

$

8,275,268

$

4,776,411

Other non-employee research and development costs

 

772,501

 

1,602,164

Employee costs

3,336,580

3,102,238

Other general and administrative costs

4,443,129

4,781,920

Net Operating Loss:

$

16,827,478

$

14,262,733

Other segment items(a)

(19,606,351)

(1,050,251)

Net (Income) Loss:

$

(2,778,873)

$

13,212,482

Reconciliation of profit or loss

Adjustments and reconciling items

Consolidated net (income) loss:

$

(2,778,873)

$

13,212,482

(a)Other segment items included in segment (income) loss include changes in warrant liability, interest income, and interest expense, and in 2024 Loss on issuance of common shares, warrants, and pre-funded warrants in July 2024 PIPE